AFMD - Affimed N.V.
IEX Last Trade
1.29
-0.010 -0.775%
Share volume: 2,382
Last Updated: Fri 27 Dec 2024 08:28:52 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$1.30
-0.01
-0.77%
Fundamental analysis
29%
Profitability
25%
Dept financing
15%
Liquidity
71%
Performance
25%
Performance
5 Days
6.72%
1 Month
-55.28%
3 Months
-62.20%
6 Months
-76.70%
1 Year
-73.10%
2 Year
-88.66%
Key data
Stock price
$1.29
DAY RANGE
$1.28 - $1.30
52 WEEK RANGE
$0.63 - $8.95
52 WEEK CHANGE
-$79.68
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Adolf Hoess
Region: US
Website: affimed.com
Employees: 200
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: affimed.com
Employees: 200
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Affimed N.V. focuses on discovering and developing cancer immunotherapies. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers.
Recent news